Recruiting

Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination

The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management, quality of life, diabetic treatment satisfaction and frequency of hypoglycemic events by combining them into a fixed-dose single pill.

ClinicalTrials.gov IDNCT06862739

PhasePHASE4

Enrollment800

SponsorNabiqasim Industries (Pvt) Ltd

Age18 Years – 80 Years

SexALL

I'm interested View official listing

Conditions studied

Diabetes Mellitus, Type 2 DM

About this study

Interventions

Combination Product: Empagliflozin+Linagliptin+Metformin — Scarcity of local population data on triple drug combination's impact on compliance, efficacy and safety in diabetic patients

Primary outcomes

Changes in HbA1c levels (03 months, 06 months)

Eligibility information

Inclusion criteria 1. Patients of any gender 2. Patients aged between 18-80 years 3. Patients having HbA1c 8 % or above 4. Patients diagnosed with type II diabetes (more than at least 06 months) 5. Patients already on at least 02 or more anti-diabetic agents 6. Patients not allergic to empagliflozin, linagliptin, or metformin Exclusion criteria 1. Patients with age less than 18 2. Patients with Type-I diabetes 3. Patients having diabetes for less than 06 months 4. Patients on GLP-1 and GIP 5. Patients who are pregnant or lactating females 6. Patients with decompensated chronic liver disease (DCLD) 7. Patients with eGFR less than 30 ml 8. Patients with end-stage heart failure (NYHA Class 4) 9. Patients who are allergic to empagliflozin, linagliptin, or metformin 10. Patients who are not willing to consent 11. Patients who are unable to give medical history

Study locations

Faisalabad clinics, Faisalabad, Punjab Province Pakistan
Aap ka Clinic, Lahore, Punjab Province Pakistan

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-05.